Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-30

FDA Approved: APIDRA — Supplemental Application (sanofi-aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for APIDRA (insulin glulisine) filed by Sanofi‑Aventis U.S. LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Apidra (insulin glulisine)

Snippet

SUPPL AP for APIDRA (INSULIN GLULISINE)